The invention provides modified DGAT1 proteins that are modified in the N terminal region upstream of the acyl Co A binding site. The modified DGAT proteins show enhanced activity without reduced protein accumulation when expressed in cells. The modified DGAT1 proteins of the invention can be expressed in cells to i...

The invention provides chimeric DGAT1 proteins comprising: a) at their N terminal ends an N terminal portion of a first DGAT1 protein and b) at their C terminal ends a C terminal portion of a second DGAT1 protein. The chimeric DGAT proteins show enhanced activity relative to at least one of the first DGAT1 protein a...

The invention provides methods and materials for increasing root biomass in a plant by increasing the expression of at least one PEAPOD protein or fragment thereof in the plant. The invention also provides methods and materials for producing a plant increased root biomass the method comprising the step of increasing...

The invention provides methods and materials for increasing at least one of root biomass and above ground biomass and in a Poaceae plant by expressing a PEAPOD protein or fragment thereof in the Poaceae plant. The invention also provides methods and materials producing a Poaceae plant with at least one of increased ...

The invention provided modified oleosins including at least one artificially introduce cysteine. The invention provided methods and compositions for producing the modified oleosins. The invention provides polynucleotides encoding the modified oleosins  and constructs and host cells comprising the polynucleotides. T...

A method of treating animals characterised by the step of introducing to the animal a single delivery device containing two or more active agents, wherein the delivery device is configured to release an effective amount of active agents over a defined time period of 3-14 days.

This invention is directed to novel binding domains of functional significance in GDF-9 and GDF-9B molecules and to agonists and antagonists which interact therewith to modulate the biological activity of these molecules to alter mammalian ovarian function and ovulation rate.

The present invention is directed to the identification of a novel domain of functional significance on the GDF-9 and GDF-9B molecules and to peptides and antibodies which interact with the domain to modulate the biological activity of these molecules to alter mammalian ovarian function and ovulation rate. ...

NA

The invention provides a novel DGAT1 protein with improved properties over known DGAT proteins particularly known DGAT1 proteins from plants. The novel DGAT1 protein of the invention can be expressed in cells to increase cellular lipid accumulation. Expression of the DGAT1 protein of the invention in cells results i...

The present invention is directed to a vaccine comprising recombinant antigens derived from the parasitic nematode Haemonchus contortus, which will raise an immune response in farmed and wild ruminants that are susceptible or predisposed to infection by one or more nematode worm species. The recombinant antigens use...